Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ: PIRS )

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning! 
Via InvestorPlace
Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847. 
Via Benzinga
Pieris Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Recap: Pieris Pharmaceuticals Q1 Earnings
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Via ACCESSWIRE
Preview: Pieris Pharmaceuticals's Earnings
Via Benzinga
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Via ACCESSWIRE
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company  
Via Benzinga
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Via ACCESSWIRE
3 Doomed Biotech Stocks Destined for Disaster
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'. 
Via Benzinga
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4... 
Via Benzinga
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Via ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Via ACCESSWIRE
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.